Efficacy and Safety of NM-702 Tablets for the Treatment of Intermittent Claudication

Inclusion Criteria:

• Stable, symptomatic, intermittent claudication due to occlusive atheroscleroticdisease of the lower extremities

• Median treadmill peak walking time between 90 and 600 seconds

Exclusion Criteria:

• Symptoms of limb threatening ischemia (ischemic rest pain, ischemic ulceration and/organgrene)

• Clinically significant pulmonary, neurological or skeletal dysfunction (e.g., lumbarcanal stenosis, emphysema, uncontrolled angina, multiple sclerosis, or gait alteringamputation) that would directly interfere or limit exercise testing

• Subjects who have had, or will require, a peripheral revascularization procedurewithin 12 weeks prior to or following treatment initiation.

• A resting blood pressure greater than 150/100 and other clinically significantresults.